Our Story 


Orum Therapeutics is a private biotech company located in Daejeon, Korea and Cambridge, Massachusetts. We are developing a novel class of therapeutic antibodies to bring new medicines to patients with unmet medical needs. Orum leverages its unique cell-penetrating antibody platform to inhibit intracellular protein drug targets that are considered undruggable by small molecule or current antibody therapeutics.

Orum (오름) means ‘ascent’ in Korean, and it represents to us the idea of climbing or moving upwards. In 2016, we were founded with the goal to discover the first antibody to inhibit RAS. The RAS gene family are the most commonly mutated oncogenes, involved in approximately 30 percent of all human cancers. Discovered nearly 35 years ago, the mutant RAS protein has been considered a highly-validated cancer drug target, but also has a reputation as being undruggable.

We named the company Orum, because we believed inhibiting RAS with antibody drugs is akin to climbing K2, the most dangerous mountain in the world. K2 was insurmountable for nearly 100 years, until its first climbers used oxygen tanks in 1952. We believe Orum has the oxygen tank, but it requires perseverance, determination and teamwork to make it happen.

Our vision is a world where undruggable targets are no longer undruggable, so no patient suffers from diseases because antibodies cannot penetrate cells.


Leadership Team


SJ Sung Joo Lee
Founder & CEO

Throughout his career at Sanofi and LG Chem, SJ has worked to improve the therapeutic landscape for various diseases, including hepatitis B, hepatocellular carcinoma (HCC), diabetes, and Alzheimer’s disease.

Peter Park
Chief Scientific Officer

Peter is a drug discovery executive working on targeted therapeutics for oncology, overseeing discovery and development of novel therapeutics based on cell-penetrating antibody platform. He is the co-inventor of Isatuximab during tenure at Immunogen.

K Ki Hwan Chang
Research Director

K is an experienced biomedical scientist with a demonstrated history of discovering antibody drugs, a couple of them in clinical trials. He has held antibodies drug discovery leadership positions at CJ, GC Pharma, and Mogam.

Yong-Sung KIM
Scientific co-founder

Yong-Sung is Professor at Ajou University and a pioneer in antibody engineering for therapeutic applications. He has published more than 95 peer-reviewed articles and holds multiple domestic and international patents.

 Board of Directors

SJ Sung Joo Lee, PhD
Chairman, Orum

Peter U. Park, PhD
Board of Director, Orum

Junghee Lim
Board of Director, Intervest